Abstracts tagged "Cohort Study"

Abstract Number: 0655 • ACR Convergence 2023
A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis
Srijana Davuluri¹, Puneet Kapoor², Swarna Nandyala², David Fiorentino³, Julia Simard⁴ and Lorinda Chung⁵, ¹Stanford University- School of Medicine, Sunnyvale, CA, ²Stanford University- School of Medicine, Palo Alto, CA, ³Department of Dermatology, Stanford University, Redwood City, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA
Background/Purpose: Lipodermatosclerosis (LDS) is a progressive manifestation of chronic venous insufficiency characterized by distinctive lower extremity changes, including an "inverted champagne bottle" appearance, skin hyperpigmentation,…
Abstract Number: 1135 • ACR Convergence 2023
The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients
Alice Kwon¹, Audrey Liu¹, Sonali Narain², Elena Katzap³ and Galina Marder², ¹Northwell Health, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Northwell Health, Great NY, NY
Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
Abstract Number: 1925 • ACR Convergence 2023
Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Helena Abodeely¹, Sandy Hong⁶, Arundathi Jayatilleke⁷, Petar Lenert⁸, T. Shawn Sato¹, Yongdong (Dan) Zhao⁹, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon¹⁰ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital For Special Surgery, New York, NY, ⁴Indiana University, Indianapolis, IN, ⁵Ohio State University Hospital, Columbus, OH, ⁶University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁷Temple University, Philadelphia, PA, ⁸University of Iowa Hospitals and Clinics, Iowa City, IA, ⁹University of Washington, Seattle, WA, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Musculoskeletal pain is a key symptom experienced by patients with SAPHO and chronic nonbacterial osteomyelitis (SAPHO-CNO), yet its relation to disease activity assessment remains…
Abstract Number: 2509 • ACR Convergence 2023
Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Kaitlin McCarter¹, Senada Arabelovic¹, Taylor Wolfgang¹, Xiaosong Wang¹, Kazuki Yoshida¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder², Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick³, Ellen Gravallese⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Dana-Farber Cancer Institute, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) stimulate the immune system to treat cancer but may cause flares of pre-existing immune-mediated inflammatory diseases. Risk factors for ICI-induced…
Abstract Number: 0382 • ACR Convergence 2023
Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation
Irini Flouri¹, Antonios Bertsias², Argyro Repa², Nestor Avgoustidis², Eleni Kalogiannaki², Sofia Pitsigavdaki³, George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
Abstract Number: 0657 • ACR Convergence 2023
The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis
Saad Ahmed, Sophie Liem, Jeska de Vries-Bouwstra and Thomas Huizinga, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiopulmonary involvement (CPI) in systemic sclerosis (SSc) is associated with significant morbidity and mortality. Early detection and timely treatment is warranted. The Six-minute walk…
Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Jennifer Hannah¹, Alexandra Lawrence², Jennifer Martinovic², Marium Naqvi², Saadia Sasha Ali³, Carmel Stock⁴, Cara Owens⁴, Anand Devaraj⁴, Louise Pollard², Sangita Agarwal², Belén Atienza-Mateo⁵, Amit Patel⁶, Alex West², Kate Tinsley², Hasti Robbie⁷, Felix Chua⁴, Boris Lams², Athol Wells⁴, Sam Norton⁷, James Galloway⁷, Elisabetta Renzoni⁴ and Patrick Gordon⁸, ¹King's College London, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³King's College Hospital, Epsom, United Kingdom, ⁴Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶King's College Hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸NHS, London, United Kingdom
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…
Abstract Number: 1994 • ACR Convergence 2023
How Is Paracetamol Prescribed in Low Back Pain and Osteoarthritis in France? Paracetamol Prescription Patterns in the Real-World General Practice
Jasque Cittée¹, Pierre Lemire², Anna Annenkova³, Jean-Yves Milon³ and Serge Perrot⁴, ¹University Paris-Est Créteil Val de Marne Department of General Medicine, Paris, France, ²IQVIA, Paris, France, ³UPSA, Rueil-Malmaison, France, ⁴Cochin Hospital, Université Paris Cité, INSERM U987, Paris, France
Background/Purpose: Lower back pain (LBP) and osteoarthritis (OA) are the most frequent musculoskeletal disorders in the general population significantly impacting patients' quality of life. An…
Abstract Number: 2516 • ACR Convergence 2023
The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Katrina Nguyen¹, Jennifer Du¹, Jiaxiao shi² and Antony Lin¹, ¹Kaiser SCAL, Fontana, CA, ²SCPMG, Pasadena, CA
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
Abstract Number: 0422 • ACR Convergence 2023
Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis
Zelin Yun¹, Chun Li² and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases in which synovitis gradually leads to polyarthritis and joint destruction. Poor response…
Abstract Number: 0665 • ACR Convergence 2023
A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody
Mridula Dilip¹, Maureen Laffoon², Yongseok Park³, Robert Lafyatis⁴, Thomas Medsger⁵, Virginia Steen⁶, Leigh Freno² and Robyn Domsic⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh School of Medicine, Verona, PA, ⁶Georgetown University School of Medicine, Washington, DC
Background/Purpose: U2RNP is a spliceosome-associated autoantibody that has in prior case reports presented with scleroderma with myositis (SSc/PM)and SLE overlap. Autoantibodies are growing in prognostic…
Abstract Number: 1169 • ACR Convergence 2023
All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
Liying Peng¹, Peng Yin², Mucong Li³, Qian Wang⁴, Yanhong wang¹, Shuang Zhou⁴, chanyuan wu⁴, Jiuliang zhao¹, Dong xu⁵, Mengtao Li³ and xiaofeng Zeng⁴, ¹Peking Union Medical College, Beijing, China, ²Chinese Center for Disease Control and Prevention, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…
Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: 2532 • ACR Convergence 2023
Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts
Charles MIDOL¹, Edgar Wiebe², Elise Siegert³, Dörte Huscher⁴, Helene Behal⁵, David Launay⁶, Eric Hachulla⁷, Eric Matteson⁸, Vincent Sobanski⁹ and Frank Buttgereit², ¹Lille University Hospital, Besançon, France, ²Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁴Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Univ. Lille, CHU Lille, Biostatistics Department, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, Lille, France, ⁷CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ⁸Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ⁹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France
Background/Purpose: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. However, the risks factors and mechanisms driving bone…
Abstract Number: 0430 • ACR Convergence 2023
A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Maria Lopez-Lasanta¹, Helena Borrell¹, Meritxell Salles Lizarzaburu², Virginia Ruiz-Esquide³, Daniel Roig⁴, Annika Nack⁵, Carolina Pérez⁶, Julia Bernardez⁷, Andrea García⁸, Joana Rovira⁹, Andrea Cuervo¹⁰, Marta Valls¹¹, Carmen Garcia¹², Sonia Minguez¹³, Rosa Morla¹⁴, Paula Estrada⁴, Melania Martinez¹⁵, Conxita Pitarch¹⁶, Noemi Busquets¹⁷, Hye Park¹⁸, Jose A Gomez-Puerta¹⁹, Susana Holgado²⁰, Nuria Montala²¹, Raimon Sanmarti³, Lourdes Mateo²⁰, Cesar Diaz²², Hector Corominas²³ and Georgina Salvador⁷, ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ³Hospital Clinic, Rheumatology, Barcelona, Spain, ⁴Hospital Moisses Broggi, Rheumatology, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital del Mar-Parc de Salut Mar, Rheumatology, Barcelona, Spain, ⁷Hospital Mutua Terrassa, Rheumatology, Barcelona, Spain, ⁸Hospital Sant Pau-Dos de Maig, Rheumatology, Barcelona, Spain, ⁹Hospital de Mollet, Barcelona, Spain, ¹⁰Hospital Granollers, Rheumatology, Barcelona, Spain, ¹¹Hospital Josep Trueta, Rheumatology, Girona, Spain, ¹²Hospital de Terrassa, Rheumatology, Barcelona, Spain, ¹³Fundació Althaia, Manresa, Spain, ¹⁴Hospital Clinic, Rheumatology, Barcelona, Barcelona, Spain, ¹⁵Hospital Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain, ¹⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ¹⁸Hospital Universitari Sant Pau, Rheumatology, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ²¹Hospital Santa Maria, Rheumatology, Lleida, Spain, ²²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²³Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain
Background/Purpose: The Janus Kinase inhibitors (JAKi) drugs are approved for use in adults with moderate to severe rheumatoid arthritis (RA). Real-world studies are necessary as…

« Previous Page
1
…
8
9
10
11
12
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].